MARATTO

article · Bulletin of the National Research Centre/Bulletin of the National Research Center

Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting

202473 citationsOpen accessMansoura University

In plain language

Tobacco smoking is a leading preventable cause of disease and death worldwide, with combustible cigarettes releasing chemicals that initiate inflammatory pathways. This review synthesises current scientific understanding of smoking-induced diseases, epidemiological trends, and clinical strategies. At a cellular level, cigarette smoke triggers oxidative stress through reactive oxygen species, causing DNA damage and activating inflammatory signalling cascades. Smoking also disrupts apoptosis and autophagy. These mechanisms are central to the development of chronic obstructive pulmonary disease, lung cancer, and cardiovascular disease. While smoking cessation is critical, current methods have limited long-term efficacy, and the impact of emerging nicotine products is unknown. Comprehensive public health efforts are needed to reduce smoking-attributable morbidity and mortality.

Key takeaways

  • Tobacco smoking is a major preventable cause of disease and death globally.
  • Cigarette smoke induces oxidative stress and inflammation at the cellular level, leading to DNA damage and disrupted cellular processes.
  • These cellular mechanisms are central to the development of conditions such as chronic obstructive pulmonary disease, lung cancer, and cardiovascular disease.
  • Smoking cessation is critical, though current methods have limited long-term efficacy, and emerging nicotine products have unknown health impacts.
  • Comprehensive public health efforts are required, encompassing prevention, screening, treatment innovation, harm reduction, and policy reform.

Why it matters

Understanding the precise cellular mechanisms by which smoking causes disease is crucial for developing more effective prevention strategies and innovative treatments. This knowledge can lead to better interventions for reducing the global burden of smoking-related illnesses and improving public health outcomes.

Commercialisation angle

The research highlights opportunities for therapeutic targeting of oxidative stress and inflammatory pathways, suggesting potential for new drug development. It also points to the need for treatment innovation in smoking cessation and harm reduction products. These areas could lead to new pharmaceutical products, medical devices, or public health programmes, benefiting patients and healthcare providers. This work appears to be at the early to applied research stage, informing future product development and policy.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

Abstract Background Tobacco smoking remains a major preventable cause of disease and death worldwide. Combustible cigarettes release thousands of chemicals that can initiate inflammatory pathways leading to smoking-related illness. This review aims to synthesize current scientific knowledge on mechanisms of smoking-induced disease, epidemiological trends, and clinical strategies from recent literature. Main body of the abstract At the cellular level, cigarette smoke triggers oxidative stress through reactive oxygen species (ROS), causing DNA damage. This provokes inflammatory signaling cascades mediated by damage-associated molecular patterns (DAMPs), receptors like RAGE and TLRs, and downstream cytokines. Smoking also disrupts apoptosis and autophagy. In the lungs, oxidative stress and inflammation from smoking play central roles in COPD pathogenesis. Smoking-induced oxidative DNA damage, chronic inflammation, and impaired immunity combine to promote lung carcinogenesis. For cardiovascular disease, smoking triggers endothelial dysfunction, platelet activation, and atherogenesis through oxidized LDL and effects on nitric oxide and adhesion molecules. Short conclusion Given the unequivocal evidence of health risks, smoking cessation is critical to reducing preventable death and disability. Both counseling and pharmacotherapy have proven efficacy for quitting, but efficacy remains limited long-term. Emerging nicotine products like e-cigarettes have unknown impacts on cessation and population health. Comprehensive efforts encompassing prevention, screening, treatment innovation, harm reduction, and policy reform focused on curbing smoking-attributable morbidity and mortality are warranted.

Research topics

  • Advanced Glycation End Products research
  • Smoking Behavior and Cessation
  • Air Quality and Health Impacts

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s42269-024-01174-6

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.